Highlights

  • Vitrafy shares rose 6.84% to AUD 2.50 on 22 May 2026, as investors reacted positively to latest operational update.
  • The company announced successful completion of its Phase II platelet cryopreservation study with the USAISR.
  • All tested protocols exceeded existing regulatory and quality guidelines for platelet use.
  • The 3% DMSO no-wash protocol achieved an average 94% post-thaw platelet recovery.
  • The study involved platelet testing from 20 donors across multiple cryopreservation protocols

Vitrafy Life Sciences Ltd (ASX:VFY) shares moved higher during the morning session on 22 May 2026, gaining 6.84% to AUD 2.50 after the company released final Phase II platelet cryopreservation results from its study conducted with the United States Army Institute of Surgical Research (USAISR).

The market appeared to react favourably to the announcement, which included independently validated study results showing that all platelet preservation protocols tested using Vitrafy’s cryopreservation ecosystem exceeded existing regulatory and quality benchmarks currently used for platelet transfusion standards.

Today’s rise adds to a broader period of momentum for the biotechnology company, with VFY shares now trading around 66.67% higher over the past 12 months as investors continue monitoring developments linked to the company’s cryopreservation technology platform and commercial pathway.

Positive Phase II Results Draw Investor Attention

The latest announcement marked the successful completion of Vitrafy’s Phase II in-vitro platelet cryopreservation study conducted in Texas by the USAISR, which operates under the Defense Health Agency in the United States.

According to the company, the study builds on previously released Phase I data and represents the largest blood platelet testing program completed to date using the Vitrafy cryopreservation ecosystem.

The results showed that all tested protocols outperformed current regulatory and quality guidelines generally applied to platelet use in humans.

Vitrafy noted that because no commercially available frozen platelet product currently exists in the market, there are no established FDA or AABB standards specifically designed for cryopreserved platelets in the United States. As a result, the preserved platelets were assessed against quality metrics commonly applied to fresh liquid-stored platelets.

The company stated that all tested protocols met or exceeded those standards.

94% Post-Thaw Recovery Emerges as Key Result

A major focus of the announcement was the performance of the company’s 3% DMSO no-wash protocol, which achieved an average 94% post-thaw platelet Recovery Rate.

According to Vitrafy, this result exceeded the recovery levels recorded under alternative protocols tested during the study.

The comparison included:

  • 94% recovery using the 3% DMSO no-wash protocol
  • 84% recovery using a 6% DMSO wash-based protocol
  • 78.9% recovery using the trehalose-based protocol

The company stated that the no-wash protocol also outperformed competing methods across critical functionality measures, including clot strength and retention of important platelet surface receptors linked to blood clotting function.

Vitrafy further noted that the 3% DMSO no-wash formulation retained nearly double the level of key platelet receptors after thawing compared with the wash protocol.

These findings appear to be central to the market’s positive response, as they may support the commercial potential of the company’s cryopreservation ecosystem in areas where traditional platelet storage remains challenging.

Why the No-Wash Protocol Matters

The company placed significant emphasis on the practical advantages associated with a no-wash platelet preservation system.

Under traditional wash-based cryopreservation methods, platelets must undergo centrifuge-based washing and reconstitution procedures to remove toxic cryoprotectant levels before use. According to Vitrafy, these processes require specialised sterile environments, equipment and trained personnel.

Vitrafy indicated that these requirements make frozen platelet use difficult in emergency or resource-constrained settings.

In contrast, the company’s no-wash solution is designed to reduce operational complexity by removing the need for specialised pre-freeze and post-thaw processing procedures.

Management believes this approach could support broader deployment opportunities across:

  • regional and rural hospitals
  • emergency response environments
  • military and battlefield settings
  • event preparedness stockpiling
  • decentralised healthcare systems

The announcement highlighted that there is currently no FDA-approved no-wash cryopreserved platelet product commercially available in the United States.

Vitrafy said the latest Phase II data positions the company to target this market gap with what it described as a differentiated and category-first offering.

Independent Validation From USAISR

Another Factor that may have strengthened investor confidence was the involvement of the United States Army Institute of Surgical Research.

The company described the study as independent military-authored validation of Vitrafy’s cryopreservation ecosystem at commercial blood storage volumes.

USAISR research lead Dr. Kristin Reddoch-Cardenas commented that effective frozen platelet capability represents an important advancement for both civilian and military trauma response settings.

According to Dr. Reddoch-Cardenas, the collaborative work with Vitrafy offers a scientific pathway toward implementing expanded frozen platelet capabilities in practical healthcare and emergency-response environments.

Vitrafy also stated that USAISR and the company intend to present the Phase II findings at international scientific conferences in the coming months, with the complete report expected to be published alongside those presentations.

FDA Registration Pathway in Focus

Vitrafy Managing Director and CEO Brent Owens said the final Phase II report provides independent validation that the company’s decentralised no-wash platelet preservation platform exceeded regulatory and quality guidelines across meaningful performance measures.

The company also highlighted that the study involved 20 donors and was conducted at commercial-scale volumes, which management suggested is an important milestone for the technology platform.

Importantly, Vitrafy stated that it plans to continue working toward FDA medical device registration during the first half of FY2027.

For investors, the regulatory pathway may remain a key area of focus moving forward, particularly as the company advances discussions around potential clinical, commercial and healthcare applications.

Understanding Vitrafy’s Technology Platform

Vitrafy Life Sciences develops cryopreservation technology designed to improve the storage and preservation of biological materials.

The company has built a proprietary cryopreservation ecosystem that includes the Guardion freezing unit alongside Lifechain™, a cloud-based software platform used to support monitoring and management throughout the preservation process.

Vitrafy’s technology aims to preserve the integrity and quality of sensitive biological samples during collection, storage and delivery.

The company operates at the intersection of biotechnology, medical preservation systems and software-enabled healthcare logistics.

Its current platelet cryopreservation work is focused on addressing logistical limitations associated with blood Supply availability, shelf life constraints and transport challenges within healthcare systems.

The ability to effectively preserve platelets for longer durations has long been viewed as a challenge within transfusion medicine because fresh platelets typically have limited storage windows and strict transportation requirements.

Vitrafy’s technology platform is designed to improve preservation quality while enabling greater flexibility across healthcare supply chains.

Investor Webinar Scheduled

As part of the announcement, Vitrafy confirmed that management would host an investor webinar on 22 May 2026 to discuss the Phase II study results and broader implications of the findings.

The session is expected to provide additional commentary around the technology, future milestones and the pathway toward regulatory progression.

Investor webinars often attract attention following biotechnology data releases, particularly when results involve independent validation or commercial-scale testing.

Market Reaction Reflects Commercial Potential

Today’s share price rise suggests investors interpreted the USAISR study outcome as a favourable operational and commercial milestone for the company.

The combination of independently validated data, high post-thaw recovery rates, and the absence of competing FDA-approved no-wash frozen platelet products appears to have supported market sentiment.

The announcement also reinforced Vitrafy’s positioning within a specialised segment of the healthcare and biotechnology market focused on cryopreservation and blood logistics.

While biotechnology companies can remain sensitive to future regulatory, commercial and execution risks, the latest study results appear to have strengthened investor focus on Vitrafy’s long-term commercial opportunity and FDA registration pathway.

With VFY shares already recording substantial gains over the past year, the latest update may further reinforce market attention on upcoming scientific presentations, regulatory developments and future commercial milestones.